The charges claim Apotex worked with other drug companies to increase and maintain the price of pravastatin, a cholesterol drug that lowers the risk of heart disease and stroke, from 2013 to 2015.
Apotex agreed to pay $24.1 million as part of a deferred prosecution agreement. Under the agreement, Apotex is required to cooperate with the government’s broader investigation into generic drug pricing and put in place a program to detect and prevent future antitrust violations.
In return, the Justice Department will defer any prosecution for three years and drop the price-fixing charge if Apotex cooperates.
Read the full news release here.
More articles on pharmacy:
CVS’ goal of opening 1,500 HealthHubs on track despite pandemic
FDA adds heartburn drug being tested to treat COVID-19 to shortage list
Drug transport costs jump 224% amid COVID-19 pandemic, survey finds
